Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4 (NASDAQ:PHAT)
· seekingalpha.com
Phathom Pharma (PHAT) Q2 2026 earnings call: VOQUEZNA growth, first operating profit, lower revenue guidance on payer friction, and pipeline updates—read...
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...